Zealand Pharma wants to be world-leading within five years
Within the next half decade, Zealand Pharma aims to be one of the world leaders in treatment of rare metabolic disorders and gastrointestinal diseases. The foundation for success will be laid this year with four late-phase programs and an upcoming launch of two self-owned drugs.
BY MARTIN HAVTORN PETERSEN
The next five years are make or break for quoted Danish biotech company Zealand Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand initiates new study with SBS drug
For abonnenter
Zealand Pharma planned for success
For abonnenter
Zealand carries out USD 89m IPO in the US
For abonnenter
